NCT07220343 Digital Phenotyping for Psychosocial Screening in Adolescents and Young Adults With Cancer
| NCT ID | NCT07220343 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Stanford University |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 25 participants |
| Start Date | 2025-01-29 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 25 participants in total. It began in 2025-01-29 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The overall goal of the proposed study is to use digital phenotyping to identify and triage at-risk patients and accelerate access to critical mental health services.
Eligibility Criteria
Inclusion Criteria: * 10-25 years old * Recent cancer diagnosis (\>2 and \<18 months since diagnosis) * Willing to carry smartphone on their person for duration of study participation * Willing to wear smartwatch for duration of study participation Exclusion Criteria: * Significant physical or mental disability that prevents completion of study activities * Lack of proficiency in English or Spanish
Contact & Investigator
Victoria Cosgrove, PhD
PRINCIPAL INVESTIGATOR
Stanford University
Frequently Asked Questions
Who can join the NCT07220343 clinical trial?
This trial is open to participants of all sexes, aged 10 Years or older, up to 25 Years, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07220343 currently recruiting?
Yes, NCT07220343 is actively recruiting participants. Contact the research team at oborge@stanford.edu for enrollment information.
Where is the NCT07220343 trial being conducted?
This trial is being conducted at Palo Alto, United States.
Who is sponsoring the NCT07220343 clinical trial?
NCT07220343 is sponsored by Stanford University. The principal investigator is Victoria Cosgrove, PhD at Stanford University. The trial plans to enroll 25 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.